Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary artery

Efficacy of empagliflozin on cardiac function in non- diabetic patients after primary PCI on LAD

two arms parallel groups design of 44 patients in each arm randomized trial with blinded recievieg 10 mg empagliflozin daily tablet or placebo

trial is designed in Tehran Heart Center. patient and the first researcher are blind to give medication and data gathering. second resercher who monitors data gathering and giving medicine is not blind. in this trial, in first 48 hours of acute MI 10 mg Empagliflozin or placebo give to patient for 3 months. first 48 hours and after three months, ehocardiography is done by an Echocardiologist and blood samples

Enery: non-diabetic patients with PPCI on LAD that are SVD: non-diabetic patients definition: 1-HbA1C<6.5 2-history of non-diabetes 3-twice FBS<100 if two of three of these exist patient is eligible for entery of trial. exclude: 1-History of serious hypersensitivity to empagliflozin or any component of the formulation; -Severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis 2-patients that have more than one vessel disease or have SVD with non-culprit lesion >70% or with SVD of LCX or RCA 3-patients 4- diabetic patients

two groups and each person recieve one tablet of 10 mg empagliflozin or placebo.

Determine decreasing of BNP in arm of reciveing empagliflozin afer three months and comparing with recieving placebo determine cardiac systolic and diastolic function after 3 months in two arms and comparing each other determine decreasing of BNP in arm of reciveing empagliflozin afer 48 thours and comparing with arm of receiving placebo determine improvement of global longitudinal srain in arm of reciveing empagliflozin afer 48 thours and comparing with arm of receiving placebo

this trial is a randomized double blind clinical trial with permuted block type of randomization. stratified randomization is done with statistical software.patients enter into blocks including four . and recieving placebo or empagliflozin randomizingly.first physician is blind about type of medication and second physician know the type of medication to find the probable side effect

patient and the first researcher are blind to give medication and data gathering. second resercher who monitors data gathering and giving medicine is not blind. in this trial, in first 48 hours of acute MI 10 mg Empagliflozin or placebo give to patient for 3 months. in the first 48 hours , all of the followings are reviewed: 1-demographic data sheet, risk factors, history of cardiovascular diseases. 2- report of angiography is reviewed from PACS. 3- contraindication of recieving of medicine is reviewed. in 48 first 48 hours and after three months, ehocardiography is done by an Echocardiologist and blood samples for FBS, CBC, BUN, Cr, BNP, HbA1C and lipid profile is given.

some of the information are shared

from 6 months afer published

for all researchers and scientists

analysis in data is allowed

hosseinisa@gmail.com

in a week of request in email, recivivig the answer